Toll Free: 1-888-928-9744

C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 60 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Review, H1 2016', provides in depth analysis on C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted pipeline therapeutics. 

The report provides comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1)
- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) Overview 7 Therapeutics Development 8 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Products under Development by Stage of Development 8 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Products under Development by Therapy Area 9 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Products under Development by Indication 10 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Products under Development by Companies 13 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Products under Development by Universities/Institutes 15 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 21 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Companies Involved in Therapeutics Development 23 AFFiRiS AG 23 ChemoCentryx, Inc. 24 Dompe Farmaceutici S.p.A. 25 Noxxon Pharma AG 26 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Drug Profiles 27 CCX-168 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 DF-2593A - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Drug to Antagonize C5aR for Periodontitis - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 EP-67 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 NOXD-19 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 NOXD-20 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecule to Target C5aR for Undisclosed Indication - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Synthetic Peptide to Antagonize C5aR for Amyotrophic Lateral Sclerosis - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Vaccine to Target C5a for Alzheimer's Disease - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Dormant Projects 40 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Discontinued Products 42 C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Featured News & Press Releases 43 Jun 01, 2016: ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 43 May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 44 Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 46 Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 46 Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial 48 Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 49 Nov 20, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA 49 Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 50 Sep 04, 2014: Two Presentations at International Conferences of Preclinical Data on NOXXON 's anti - C5a Spiegelmer, a Potential Drug in Pneumococcal Pneumonia - Induced S epsis 51 Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 52 Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements 52 Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis 53 Dec 07, 2012: Penn-Led Research Suggests A New Strategy To Prevent Or Halt Periodontal Disease 55 May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress 56 Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis 57 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 22 Pipeline by AFFiRiS AG, H1 2016 23 Pipeline by ChemoCentryx, Inc., H1 2016 24 Pipeline by Dompe Farmaceutici S.p.A., H1 2016 25 Pipeline by Noxxon Pharma AG, H1 2016 26 Dormant Projects, H1 2016 40 Dormant Projects (Contd..1), H1 2016 41 Discontinued Products, H1 2016 42


List of Figures
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Mechanism of Actions, H1 2016 18 Number of Products by Stage and Mechanism of Actions, H1 2016 18 Number of Products by Stage and Routes of Administration, H1 2016 20 Number of Products by Molecule Types, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 21

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify